Literature DB >> 15667578

Peroxisome proliferator-activated receptor gamma: the more the merrier?

C A Argmann1, T-A Cock, J Auwerx.   

Abstract

The consequence of activating the nuclear hormone receptor, peroxisome proliferator-activated receptor gamma (PPARgamma), which coordinates adipocyte differentiation, validates the concept, 'you are what you eat'. Excessive caloric intake leads to fat formation if the energy from these nutrients is not expended. However, this evolutionary adaptation to store energy in fat, which can be released under the form of fatty acids, potent PPARgamma agonists, has become a disadvantage in today's affluent society as it results in numerous metabolic imbalances, collectively known as the metabolic syndrome. With the surge of human and genetic studies on PPARgamma function, the limitations to the benefits of PPARgamma signalling have been realized. It is now evident that the most effective strategy for resetting the balance of this thrifty gene is through its modulation rather than full activation, with the goal to improve glucose homeostasis while preventing adipogenesis. Finally, as more PPARgamma targeted pathways are revealed such as bone homeostasis, atherosclerosis and longevity, it is most certain that the PPARgamma thrifty gene hypothesis will evolve to incorporate these.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15667578     DOI: 10.1111/j.1365-2362.2005.01456.x

Source DB:  PubMed          Journal:  Eur J Clin Invest        ISSN: 0014-2972            Impact factor:   4.686


  26 in total

Review 1.  Peroxisome proliferator-activated receptors ligands and ischemia-reperfusion injury.

Authors:  Rosanna Di Paola; Salvatore Cuzzocrea
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-03-13       Impact factor: 3.000

2.  Amorfrutins are potent antidiabetic dietary natural products.

Authors:  Christopher Weidner; Jens C de Groot; Aman Prasad; Anja Freiwald; Claudia Quedenau; Magdalena Kliem; Annabell Witzke; Vitam Kodelja; Chung-Ting Han; Sascha Giegold; Matthias Baumann; Bert Klebl; Karsten Siems; Lutz Müller-Kuhrt; Annette Schürmann; Rita Schüler; Andreas F H Pfeiffer; Frank C Schroeder; Konrad Büssow; Sascha Sauer
Journal:  Proc Natl Acad Sci U S A       Date:  2012-04-16       Impact factor: 11.205

3.  Developmental programming: differential effects of prenatal testosterone excess on insulin target tissues.

Authors:  Shadia E Nada; Robert C Thompson; Vasantha Padmanabhan
Journal:  Endocrinology       Date:  2010-09-15       Impact factor: 4.736

Review 4.  Peroxisome proliferator-activated receptors, metabolic syndrome and cardiovascular disease.

Authors:  Salman Azhar
Journal:  Future Cardiol       Date:  2010-09

Review 5.  Mechanisms of anti-inflammatory and neuroprotective actions of PPAR-gamma agonists.

Authors:  Ramya Kapadia; Jae-Hyuk Yi; Raghu Vemuganti
Journal:  Front Biosci       Date:  2008-01-01

Review 6.  PPARgamma in human and mouse physiology.

Authors:  Sami Heikkinen; Johan Auwerx; Carmen A Argmann
Journal:  Biochim Biophys Acta       Date:  2007-03-27

Review 7.  The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis.

Authors:  Hebe N Gouda; Gurdeep S Sagoo; Anne-Helen Harding; Jan Yates; Manjinder S Sandhu; Julian P T Higgins
Journal:  Am J Epidemiol       Date:  2010-02-23       Impact factor: 4.897

8.  Amorfrutin B is an efficient natural peroxisome proliferator-activated receptor gamma (PPARγ) agonist with potent glucose-lowering properties.

Authors:  C Weidner; S J Wowro; A Freiwald; K Kawamoto; A Witzke; M Kliem; K Siems; L Müller-Kuhrt; F C Schroeder; S Sauer
Journal:  Diabetologia       Date:  2013-05-18       Impact factor: 10.122

Review 9.  Atherosclerosis and cardiovascular risk reduction with PPAR agonists.

Authors:  Johanna Kuusisto; Laura Andrulionyte; Markku Laakso
Journal:  Curr Atheroscler Rep       Date:  2007-10       Impact factor: 5.113

10.  Interaction between peroxisome proliferator- activated receptor gamma polymorphism and overweight on diabetic retinopathy in a Chinese case-control study.

Authors:  Yan Wang; Xin-Hua Wang; Ruo-Xi Li
Journal:  Int J Clin Exp Med       Date:  2015-11-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.